Skip to content
Assyro AI
Regulatory Intelligence Platforms: November 2026 Buyer Guide
regulatory intelligence platform
regulatory intelligence database
regulatory intelligence software

Regulatory Intelligence Platforms: November 2026 Buyer Guide

Comparison

Compare nine regulatory intelligence options by research, monitoring and change assessment, with a worked evaluation exercise and buying worksheet.

Assyro Team
18 min read

Quick Answer

Choose a regulatory intelligence platform around the work you need to complete: researching requirements, monitoring official changes, assessing product impact, or implementing an approved response. Compare the exact sources, product scope, version history and downstream records. Assyro is a conditional document-workflow option; dedicated monitoring and automated product-impact assessment are not confirmed capabilities in this comparison.

A useful alert should help someone answer three questions: what changed, does it apply to our product, and who owns the response? A database, a news service and an assessment workflow may each contribute, but they need different acceptance criteria.

Disclosure and method: Assyro publishes this guide and appears first. The comparison uses official vendor descriptions and documentation checked on October 6, 2026. It is a documentary assessment, not a hands-on benchmark. Features described by vendors still require confirmation for your contracted edition, coverage and configuration. The original exercise below is available entirely in this article.

Compare the nine options by the job you need done

These nine options cover the research, monitoring and operational categories in the existing shortlist. They are not an exhaustive market ranking. The final column identifies an evaluation question, not an assertion that a feature is absent.

Comparison table with columns Option, Documented or eligible starting point, Decisive buying question
OptionDocumented or eligible starting pointDecisive buying question
AssyroDocument workflow after a regulatory decisionCan the agreed document work be demonstrated without depending on unconfirmed monitoring or automated impact features?
Clarivate Cortellis Regulatory IntelligenceRegulatory content, with documented external search/summarization accessWhich subscription rights, source references and access controls follow the content into your assistant?
RegDeskDevice-focused change assessment and implementation workflowDoes the contracted scope cover your product category and product/country records?
IQVIA Regulatory IntelligenceRequirements research, comparisons, alerts and internal knowledgeCan you distinguish current external requirements from your own interpretation?
ArisGlobal LifeSphere Regulatory IntelligenceSource monitoring, classification and regulatory-record impactWhich product records and sources drive the proposed assessment?
Freyr freya.IntelligenceResearch and alerts, with assessment/workflow differentiated by planAre the required operations included in Plus or Corporate?
Redica SystemsRegulatory intelligence and collaborative change assessmentDoes the assessment retain its evidence when handed to your RIM or quality system?
Citeline Pink SheetEditorial analysis, reporting and regulatory trackersWhich decisions need editorial context, and which need a separate controlled assessment?
Obsidian RIOfficial-source monitoring and team notificationsAre your specific sources covered, and how does an alert become an owned action?

Separate research, monitoring, assessment and implementation

Research answers a question such as which evidence a particular market expects. Evaluate source quality, revision dates, country comparisons and the distinction between expert interpretation and official text.

Monitoring identifies changes within an agreed source list. Evaluate draft-to-final transitions, duplicate detection, publication dates and failed source retrieval. A large country count does not establish coverage of the specific agency page that matters to your product.

Assessment connects a change to product, market and lifecycle information. Evaluate the rationale for applicability, treatment of missing data and reviewer decisions. Receiving an email is not evidence that an assessment occurred.

Implementation moves an accepted decision into controlled work: a revised document, assigned task or updated registration record. Decide where the authoritative record belongs. Our regulatory information management guide explains that broader system boundary; the regulatory affairs software comparison covers adjacent software categories.

The vendor differences worth evaluating

1. Assyro: a conditional option for document follow-through

Assyro belongs on the shortlist when the scoped problem is preparing and managing documents after your team has interpreted a regulatory change. Its document-management offering is the relevant starting point. Treat this as a downstream workflow discussion, with the intelligence source and regulatory decision supplied by your established process.

Dedicated regulatory-intelligence monitoring, automatic product-impact assessment and a standalone intelligence database are not confirmed for this guide. EMA submission support remains on the roadmap. A procurement requirement for operational EMA support or automatic global change surveillance therefore cannot be marked satisfied by the Assyro profile.

For a useful demonstration, bring one approved assessment, its cited source and the specific document that needs revision. Ask the team to show which agreed document operations are available now, how the source and decision remain accessible, and where approval responsibility sits. Record any manual steps or integrations in the proposal.

This scope can suit a team whose bottleneck is documentary follow-through. If the missing capability is discovering changes in the first place, evaluate a dedicated intelligence provider for that requirement before assessing Assyro's role.

2. Clarivate Cortellis: regulatory content with documented assistant access

Clarivate's current Cortellis Regulatory Intelligence connector documentation describes tools for searching and summarizing its regulatory content through an external AI interface. It explicitly requires a valid Cortellis Regulatory Intelligence subscription. That is a more useful integration fact than labeling the product a closed database.

The buying decision has two parts: whether the content answers your regulatory questions and whether your intended interface preserves the evidence needed to review the answer. Access through an assistant does not itself establish a product-impact workflow or an approved implementation record.

Use one country-specific question and one comparison across markets. Ask the presenter to open the source behind each conclusion, show its revision and identify any interpretation added by the service. Then repeat the question from your proposed assistant environment with the intended user's permissions.

Request the applicable content license and connector entitlements in the quote. If a reviewer loses access to the underlying document after an answer is shared, the apparent convenience creates a separate review problem. Assess that boundary before choosing a deployment model.

3. RegDesk: inspect the product and country model

RegDesk's current change-management page describes a sequence covering assessment, strategy, approval and creation of implementation workflows. Its public positioning emphasizes medical devices, including changes tracked by product, country and SKU. Its main site also describes API connectivity; integration should be evaluated, not assumed absent. RegDesk's change-management description.

For a device portfolio, the useful question is whether one assessed change can lead to appropriately different country actions while retaining the central rationale. For a medicines-only team, confirm the relevant content and workflows explicitly; a broad regulatory label does not establish pharmaceutical coverage.

Give the presenter a product record missing a market or classification field. Ask whether the resulting assessment requests clarification or silently assumes a value. Then change the product's country list and inspect what happens to the assessment and its tasks.

Require a demonstration using the same record types that your team would maintain. A well-presented workflow with sample device data cannot settle fit for a different product category or an incomplete registration inventory.

4. IQVIA: compare external requirements and internal knowledge

IQVIA describes requirements research covering human drugs, biologics, devices and in vitro diagnostics, with country comparisons, document-version alerts and the ability to add internal knowledge. Those operations make it a candidate for teams combining external regulatory research with their own precedents. IQVIA Regulatory Intelligence.

The important boundary is provenance. An internal interpretation may be valuable without being the authority's position, and a historical company precedent may no longer answer today's question.

Build a comparison for two markets, then add an internal note that deliberately conflicts with a newer source. Ask the presenter to identify the conflict, show both dates and explain which information a search result prioritizes. Evaluate whether a reviewer can follow the answer back to its underlying material.

For the commercial discussion, specify the countries, product types, users and internal-content functionality required. Ask separately about task handoff and the destination of approved assessments. Do not assume that buying a research subscription also supplies your chosen implementation process.

5. ArisGlobal LifeSphere: connect monitoring to the right records

The LifeSphere Regulatory Intelligence page describes monitoring predefined online sources, downloading and classifying updates, impact assessment on regulatory records and a conversational interface. These are specific vendor-described operations; they deserve a scoped demonstration rather than a generic AI comparison. ArisGlobal product description.

Ask which regulatory records the assessment reads, where they originate and how their completeness is checked. If the portfolio data is stale, even an accurate source summary can produce an inappropriate product association.

Use the same source change with two records: one clearly in scope and one with an unknown dosage form. Require the presenter to show the proposed impact, the supporting text and the reviewer correction path. Then correct the missing field and inspect whether the prior decision is retained in the history.

Have the proposal identify the modules, data preparation and configured sources required for this flow. The documented ability to assess a regulatory record is a useful starting point; it is not evidence that every record in your estate is already connected or that an automatic assessment is correct.

6. Freyr freya.Intelligence: compare the actual plans

Freyr's public plan comparison makes an important distinction. Plus lists research, document chat, dashboards and alerts. Corporate adds collaborative workflows, impact assessment, responses to queries and document management, and lists a minimum of 20 users. These are the terms displayed when checked, not a negotiated quote. freya.Intelligence plans.

This distinction should shape the demonstration. A team primarily buying research and alerts may evaluate a different scope from one needing an owned assessment through implementation. Ask the vendor to label each demonstrated operation with the plan or service that supplies it.

Run a change from source retrieval through reviewer disposition and assignment. If a step uses a separate service, module or configuration, record that dependency next to the result. A bundled presentation can otherwise obscure which part of the proposed contract delivers the outcome.

Compare total required seats and implementation effort alongside the subscription. Ask for current terms in writing rather than calculating a purchasing decision from a promotional price. The useful comparison is the cost of your required workflow, including its people and dependencies.

7. Redica Systems: assess the workflow beyond enforcement data

Redica's current regulatory-intelligence page goes beyond inspection research. It describes change summaries, document-version comparison, draft-to-final monitoring and collaborative assessments with rationale and evidence. It also describes connections to RIM and quality environments. An inspection-only label would miss that stated scope. Redica Regulatory Intelligence.

This makes it worth evaluating when regulatory and quality teams need to reach and retain a decision together. Separate the quality of the source intelligence from the fidelity of the downstream handoff.

Ask two reviewers to disagree on an assessment, resolve the disagreement and send the accepted result to the proposed destination system. Inspect the destination: does it contain the source revision, reasoning and accountable owner, or only a short notification? Check what happens when a source is updated again after approval.

For procurement, identify which integrations and assessment operations are included in your scope. A documented integration direction does not specify your field mapping, permissions or ownership of failed transfers. Those details determine whether the workflow is usable in your environment.

8. Citeline Pink Sheet: editorial context for regulatory decisions

Pink Sheet describes regulatory reporting, analysis, interviews and trackers. That can support a different buying need from a source-monitoring or controlled-assessment system: understanding the context around policy developments and agency decisions. Citeline's Pink Sheet description.

Evaluate it with a decision that needs interpretation across several developments. Ask your reviewers whether the coverage identifies questions they would otherwise miss and whether they can separate reported analysis from the underlying official material. Editorial value is not measured by counting automated tasks.

When an article informs an operational decision, retain the primary source and your own applicability assessment alongside it. Confirm subscription access for everyone expected to review or share the analysis; do not assume the same rights for all readers.

Approval tracking is a related but distinct use case. Our 2026 PDUFA calendar and FDA approval timeline guide help frame scheduling questions. Neither an approval date nor an editorial report, by itself, determines the effect of a guidance change on your dossier.

9. Obsidian RI: evaluate the exact monitoring perimeter

Obsidian RI describes monitoring official sources, identifying regulatory lifecycle stages and delivering notifications into team channels. Its stated model makes source coverage and alert routing the first things to investigate. Obsidian RI.

Write down the actual agency pages, document collections, jurisdictions and languages you need before comparing its coverage. A broad industry description is less useful than an agreed list with a clear process for adding or retiring sources.

For the demonstration, choose a source with a draft and final version, a document moved to a new URL and an unavailable page. Ask how each event appears to the recipient. A silent retrieval failure must be distinguishable from a source with no changes.

Then trace one relevant notification into your assessment process. Delivery to a team channel establishes receipt capability; your evaluation must separately establish ownership, review and closure. If those operations live elsewhere, document the handoff and its cost. A focused monitoring service can still fit well when that boundary is deliberate.

Run this three-document change-assessment exercise

This is an original, entirely fictional training packet. The Harbor Medicines Office, guidance and products below do not exist. Copy the complete packet into your evaluation; no download is required. The assessment date is October 6, 2026.

Source packet

Document G1 - Final guidance, revision 1. Published January 15, 2024; application date July 1, 2024. Title: Batch Evidence Summary for Sterile Injectable Applications. Issuer: Harbor Medicines Office. Section 2: “For new marketing applications for sterile injectable medicines in Harbor, the recommended batch evidence summary contains the batch identifier and storage condition. This guidance does not cover oral medicines or variations.” Status in this packet: superseded by G2 for applications submitted on or after October 1, 2026; retain for historical assessments.

Document G2 - Final guidance, revision 2. Published September 1, 2026; application date October 1, 2026. Issuer: Harbor Medicines Office. Title: Batch Evidence Summary for Sterile Injectable Applications. Section 2: “For new marketing applications for sterile injectable medicines in Harbor submitted on or after October 1, 2026, the recommended batch evidence summary contains the batch identifier, storage condition and source-record revision identifier. This replaces revision 1 for those applications. Oral medicines and variations remain outside scope.” These are recommendations in this fictional guidance, not legislation.

Document G3 - Draft guidance, revision 3. Published October 2, 2026; comment deadline October 31, 2026. Issuer: Harbor Medicines Office. Title: Batch Evidence Summary for Sterile Injectable Applications. Section 2 proposal: “Add a manufacturing-site identifier to the batch evidence summary.” Proposed application date: January 1, 2027. Status: consultation draft, with no adopted application date. The draft does not replace G2.

Portfolio and expected applicability

Assume no other sources or transition provisions in this exercise. Do not infer missing product data.

Comparison table with columns Record, Supplied facts, Correct result on October 6
RecordSupplied factsCorrect result on October 6
ASterile injectable; Harbor; new application planned October 20, 2026G2 applies to planning this application; assess addition of source-record revision identifier
BSterile injectable; Harbor; new application submitted September 20, 2026G1 governed the packet's recommendation at submission; retain historical rationale; G2 text alone does not establish retrospective action
COral tablet; Harbor; new application planned October 20, 2026Outside the explicit scope of this guidance; record the exclusion reason
DHarbor; new application planned October 20, 2026; dosage form missingApplicability unresolved; request dosage-form evidence before deciding

The newest publication is G3, but it is not the operative final version. September 1 is G2's publication date; October 1 determines its stated application boundary. G1 must remain retrievable for B's historical record. For a strategy spanning several markets, repeat this reasoning per jurisdiction rather than copying Harbor's outcome; see our global regulatory strategy guide.

Worked assessment and action record

For A, the accepted assessment should identify one new recommended data element: the source-record revision identifier. It should not add the draft manufacturing-site field to the current implementation task. It should also avoid calling the recommendation a new legal obligation.

Comparison table with columns Field, Worked result
FieldWorked result
Assessment IDSYN-RI-01, explicitly synthetic
EvidenceG1 section 2 compared with G2 section 2; retain G3 separately as a draft watch item
Applicable recordA; sterile injectable, Harbor, new application, planned October 20
Decision and rationaleAdopt G2's recommended summary structure for A; filing date falls after October 1
Reviewer dispositionRegulatory lead accepts this synthetic assessment; document-owner completion requires a separate review
OwnerRegulatory lead; document owner prepares the revision
ActionRevise the batch-summary template and A's draft summary to include source-record revision identifiers
Target dateOctober 12, an internal planning target, not an agency deadline
Completion evidenceReviewed template revision plus A's completed summary with traceable identifiers
Worked statusAssessment accepted in the exercise; implementation remains open until completion evidence is reviewed

“Assessment accepted” and “change implemented” are different states. A system that closes the action merely because someone accepted the assessment fails this exercise's completion criterion.

For real FDA material, status also needs careful interpretation: FDA explains that guidance generally presents nonbinding recommendations unless specific statutory or regulatory requirements are cited. A “final” badge alone does not establish a binding obligation. FDA explanation of guidance documents.

Add the negative and missing-data controls

Repeat the exercise with D's dosage form still missing. Passing behavior is an unresolved assessment with a request for the missing fact, not a confident “no impact.” Supply the dosage form later and require a traceable reassessment.

Check the exact date boundary: an otherwise eligible application submitted September 30 falls under G1 in this packet; one submitted October 1 falls under G2. Change the submission type to a variation and the explicit exclusion applies. These outcomes follow the supplied text, not the newest publication date.

Next, withhold G2's full text and supply only a summary saying “batch guidance updated.” The reviewer cannot establish the exact new field or exclusions from that summary. The correct outcome is to obtain the source before accepting the detailed assessment.

Finally, remove the issuer from G3 and add a duplicate copy of G2. The first needs identity verification; the second must not create a second implementation action for the same accepted change. Record failures and the required configuration or process correction. These are proposed buyer tests, not results obtained from any named vendor.

Copy this evaluation worksheet into your procurement record

Complete one worksheet per candidate and contracted configuration. Use demonstrated, partial, failed, or not evaluated for each result. Attach evidence; a vendor statement alone is not a demonstrated result.

Comparison table with columns Decision field, What to enter, Acceptance evidence
Decision fieldWhat to enterAcceptance evidence
Required jobResearch, monitoring, assessment, implementation; mark mandatory operationsAgreed scope with the buyer's owner
CoverageProduct categories, jurisdictions, languages and exact official sourcesReviewed source list and exclusions
Commercial scopeEdition, modules, seats, services, integrations and renewal assumptionsWritten proposal mapping each operation to its entitlement
Source identityIssuer, document ID, revision and accessible underlying textG1/G2/G3 individually retrievable
Dates and statusPublication, application, consultation and supersession fieldsG3 remains draft; G2's two dates remain distinct
ApplicabilityProduct, market, submission type and missing attributesA–D outcomes match the worked reasoning
Decision recordEvidence, rationale, reviewer and dispositionAccepted assessment remains explainable after review
ImplementationOwner, target, required artifact and closure authorityTask stays open until completion evidence is accepted
Handoff and exitDestination fields, permissions, error handling and export rightsSource revision and rationale survive export or transfer
Unresolved gapsMissing evidence, accountable person and resolution dateMandatory gaps resolved before final selection

A mandatory failure should not disappear inside an average score. Keep unresolved coverage or applicability gaps visible, even when users like the interface. For optional features, record the value and cost without turning them into substitutes for mandatory evidence.

Compare the cost of the complete workflow

Ask each shortlisted vendor to quote the same operating scenario: named markets and sources, product records, reviewer seats, expected integrations and implementation responsibilities. Include data preparation, configuration, content licensing, support and the work your own team must perform between systems.

Agree who maintains the source list and product attributes after purchase. Ask how unavailable sources, reassigned owners and superseded assessments are surfaced. Establish whether source documents and decision records remain accessible when users leave or a subscription ends.

Choose the candidate whose demonstrated scope closes your actual gap. A research team may prioritize reliable cross-market answers; an operations team may prioritize traceable assessment and task closure. Where your need is carrying an already assessed change into controlled document work, discuss that specific workflow with Assyro, bringing the source, accepted rationale and document to be revised.

About the author

Assyro Team

Expert regulatory operations consultants helping pharmaceutical companies navigate complex compliance challenges.

Related articles

Demos available this week